Navigation Links
Global Biopharma Mergers & Acquisition and Deal Making Report 2013: Understanding the Latest Trends to Optimize Future Strategy
Date:9/25/2013

DUBLIN, September 25, 2013 /PRNewswire/ --

Research and Markets
(http://www.researchandmarkets.com/research/ffq62m/biopharma_manda) has announced the addition of the "Biopharma M&A and Deal Making: Understanding the Latest Trends to Optimize Future Strategy" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769)

The report, Biopharma M&A and Deal Making, was written to support team and corporate strategic initiatives around the options that exist to grow revenues through externalization, whether by M&A or licensing. CBR Pharma Insights provides in-depth analysis on the deals being done today, the trends being seen over time, and the strategies employed throughout the industry.

The leading pharmaceutical players continue to face the combined threats of a difficult operating environment and patent losses while struggling to deliver on pipeline potential. Externalization strategies are a key means to boost future revenues and, indeed more imminently, to satisfy shareholder demands. However, the increasing size of the leading biopharmaceutical companies is necessitating their involvement in growing the numbers and size of deals year by year. This in itself, along with the rising financial firepower of the mid-tier players, has increased the level of competition for the most attractive targets.

Increased competition in the marketplace for M&A and licensing deals can artificially inflate the cost of these deals, distorting the balance of value, risk and return. As a result companies must employ more rigorous selection processes and expand search criteria to consider more diverse options if they are to maximize their returns on investment.

Key Reasons to Purchase

- Understand and evaluate the strategies being used by companies of all sizes to support future revenue growth
- Benefit from CBR's case study analysis of the different types of deals being done in the current & future biopharma industry
- Access data and trends analysis of the types of deals taking place and which therapeutic areas are showing the most activity
- Gain insights around the steps that need to be taken in order to best secure a successful deal
- Learn who the key companies are to watch for in the coming year, the motivations behind the deals they are doing, and identify which ones relate to your business strategies

Key Topics Covered:

Chapter 1: Introduction
- What is driving the increased use of externalization in biopharma industry strategies
- Externalization strategies: the options
- Benefits of different deal types from M&A to arm's length licensing

Chapter 2: Trends in recent deal activity
- M&A deal trends
- Key acquisitions in 2012 and the motives behind them
- Most acquisitive companies
- Licensing deal trends (Type of deal, Therapy area, Phase)
- Divesting - the other extreme
- Focus on: Deal activity in the generics sector

Chapter 3: Successful deal making
- Key steps to successful deal making
- Shift to earlier stage deals
- Differentiating capabilities to position company as "partner of choice"
- Focus on: Joint ventures in emerging markets

Chapter 4: Future deal activity
- Key companies to watch in 2013

Appendix


For more information visit http://www.researchandmarkets.com/research/ffq62m/biopharma_manda.

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
U.S. Fax: +1-646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals


'/>"/>
SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Global Genomics Group (G3) and Illumina to Partner on Cardiovascular Genomics
2. Health Care Equipment & Supplies: Global Industry Guide
3. Sequenom Announces Global Certified Service Provider Program
4. InspireMD Appoints David Blossom as Vice President of Global Marketing and Strategy
5. Global Markets for Emerging Insulin Drug and Delivery Technologies - Focus on Syringes and Vials
6. Global Markets for Contract Pharmaceutical Manufacturing, Research and Packaging - Focus on Contract Packaging
7. Shire to Present at the Bank of America Merrill Lynch Global Health Care Conference
8. Synthetic Biologics to Present at the First Global Life Sciences Conference in Warsaw, Poland
9. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch Global Healthcare Conference
10. Quest Diagnostics to Speak at the Morgan Stanley Global Healthcare Conference
11. Shire to Present at the Morgan Stanley Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... 2, 2017  Eli Lilly and Company (NYSE: ... the third quarter of 2017 on Tuesday, October 24, ... that day with the investment community and media to ... conference call will begin at 9 a.m. Eastern time. ... live webcast of the conference call through a link ...
(Date:10/2/2017)... -- Halo Labs announces the European launch of their new low ... MIBio 2017 in Cambridge, U.K on October ... biopharmaceutical samples with unprecedented speed and sensitivity while using far less ... Imaging. ... analysis system ...
(Date:9/28/2017)... 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), will ... and webcast on Friday, November 3, 2017, beginning at ... at approximately 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... financial performance and guidance for 2018, Hill-Rom executives will ... operational performance, and long-range financial outlook through 2020. ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has ... least understood books in the Holy Scriptures, Revelation. The Book of Revelation paints a ... centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins says that ...
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of a ... “The Journey: From the Mountains to the Mission Field” is the creation of published ... all ages and currently teaches a class of ladies at her church, which she ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... now treating sleep apnea using cutting-edge Oventus O2Vent technology. As many ... sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer significant ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( ... today the introduction of an innovative new design of the shoulder pad. The ... get maximum comfort while controlling your pain while using cold therapy. By utilizing ice ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information ... we intend to develop to enable prevention of a major side effect of ... loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label ...
Breaking Medicine News(10 mins):